Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Parallel Group, Double Blind, Multiple Dose, Placebo Controlled Study to Assess the Efficacy and Safety of MNK-1411 in Male Participants 4 to 8 Years of Age With Duchenne Muscular Dystrophy

Trial Profile

A Multicenter, Randomized, Parallel Group, Double Blind, Multiple Dose, Placebo Controlled Study to Assess the Efficacy and Safety of MNK-1411 in Male Participants 4 to 8 Years of Age With Duchenne Muscular Dystrophy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2019

At a glance

  • Drugs Tetracosactide (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Therapeutic Use
  • Acronyms BRAVE
  • Sponsors Mallinckrodt plc
  • Most Recent Events

    • 02 Aug 2018 According to a Mallinckrodt plc media release, first patient has been enrolled in this study.
    • 26 Feb 2018 Planned End Date changed from 1 Apr 2021 to 1 Aug 2020.
    • 26 Feb 2018 Planned primary completion date changed from 1 Mar 2021 to 1 Aug 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top